Werewolf Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Werewolf Therapeutics, Inc. filed a Form 8-K on May 4, 2021, in connection with the closing of its initial public offering of common stock. The filing reports amendments to the Company’s certificate of incorporation and bylaws. The Company’s common stock trades on the Nasdaq Global Select Market under the symbol HOWL.
Financial and Operating Metrics
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial performance metrics. It also does not provide an operating forecast or financial guidance.
Material Changes
- The Company filed a Restated Certificate of Incorporation effective upon the IPO closing.
- Authorized common stock increased to 200,000,000 shares.
- The Company eliminated references to its previously existing preferred stock and authorized 5,000,000 shares of undesignated preferred stock, issuable in one or more series by the board of directors.
- The board of directors became classified into three classes with staggered three-year terms.
- Directors may be removed only for cause and by a two-thirds stockholder vote.
- Board vacancies may be filled only by a majority vote of the directors then in office.
- Stockholders may no longer act by written consent in lieu of a meeting or call special meetings of stockholders.
- Specified amendments to the Restated Certificate or bylaws require approval by holders of at least two-thirds of the voting power entitled to elect directors.
- The Restated Certificate establishes Delaware courts as the exclusive forum for specified internal corporate claims, subject to stated exceptions, and federal district courts as the exclusive forum for Securities Act claims unless the Company consents to another forum.
- Amended and Restated Bylaws became effective upon the IPO closing. They establish procedures for stockholder proposals and director nominations and conform the bylaws to the Restated Certificate.
Outlook, Risks, and Unusual Items
The filing contains no management commentary, guidance, contingencies, or clinical and operating outlook. The classified board, supermajority voting provisions, restrictions on stockholder actions, and exclusive-forum provisions may reduce stockholder ability to effect corporate changes or bring certain claims in alternative venues.
Important Facts to Verify
- Confirm the IPO closing date and related offering terms in the Company’s registration statement and prospectus.
- Review Exhibits 3.1 and 3.2 for the complete Restated Certificate of Incorporation and Amended and Restated Bylaws.
- Verify the authorized share counts and the rights and preferences of any preferred stock series subsequently designated by the board.
- Assess the practical implications of the classified board, director-removal restrictions, supermajority requirements, and exclusive-forum provisions.